Fortress Biotech (FBIO) stock price, revenue, and financials

Fortress Biotech market cap is $247.4 m, and annual revenue was $36.63 m in FY 2019

$247.4 M

FBIO Mkt cap, 26-May-2020

$12.9 M

Fortress Biotech Revenue Q1, 2020
Fortress Biotech Gross profit (Q1, 2020)9.1 M
Fortress Biotech Gross profit margin (Q1, 2020), %70.5%
Fortress Biotech Net income (Q1, 2020)-24.1 M
Fortress Biotech EBIT (Q1, 2020)-21.5 M
Fortress Biotech Cash, 31-Mar-2020135.9 M
Fortress Biotech EV223.4 M

Fortress Biotech Revenue

Fortress Biotech revenue was $36.63 m in FY, 2019 which is a 36.3% year over year increase from the previous period.

Embed Graph

Fortress Biotech Revenue Breakdown

Embed Graph

Fortress Biotech revenue breakdown by business segment: 18.7% from Other Branded, 76.6% from Targadox and 4.7% from Other

Fortress Biotech Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019

Revenue

187.6m26.9m36.6m

Revenue growth, %

(86%)36%

Cost of goods sold

3.7m6.1m10.5m

Gross profit

183.9m20.8m26.1m

Gross profit Margin, %

98%77%71%

R&D expense

56.7m87.4m81.3m

General and administrative expense

40.5m53.4m55.6m

Operating expense total

285.1m140.8m136.9m

EBIT

(101.2m)(120.0m)(110.8m)

EBIT margin, %

(54%)(446%)(303%)

Interest expense

7.9m8.5m

Interest income

819.0k1.1m2.6m

Pre tax profit

(98.3m)(141.9m)(101.7m)

Income tax expense

1.5m

Net Income

(99.8m)(141.9m)(101.7m)

EPS

(1.6)(1.9)(0.7)

Fortress Biotech Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019

Cash

113.9m65.5m136.9m

Accounts Receivable

7.8m5.5m13.5m

Prepaid Expenses

12.7m6.7m4.1m

Inventories

171.0k678.0k857.0k

Current Assets

183.2m111.2m156.3m

PP&E

9.5m12.0m12.4m

Goodwill

18.6m

Total Assets

246.0m141.0m226.4m

Accounts Payable

36.1m34.1m35.5m

Short-term debt

14.2m20.4m10.1m

Current Liabilities

67.4m55.6m45.6m

Long-term debt

43.2m60.4m101.1m

Total Debt

57.4m80.8m111.3m

Total Liabilities

125.4m121.3m153.9m

Common Stock

551.0k717.0k574.0k

Preferred Stock

1.0k1.0k1.0k

Additional Paid-in Capital

364.1m397.4m461.9m

Retained Earnings

(312.1m)(396.3m)(436.2m)

Total Equity

120.5m19.7m72.5m

Debt to Equity Ratio

0.5 x4.1 x1.5 x

Debt to Assets Ratio

0.2 x0.6 x0.5 x

Financial Leverage

2 x7.1 x3.1 x

Quarterly

USDQ2, 2013Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

67.9m134.0m144.3m110.5m124.0m98.6m95.9m116.4m149.4m134.9m135.9m

Accounts Receivable

1.4m3.3m5.6m8.3m5.3m5.4m8.0m3.1m5.1m15.8m

Prepaid Expenses

243.0k8.5m11.9m10.7m14.3m13.9m14.1m4.3m3.4m4.1m4.5m

Inventories

204.0k299.0k318.0k222.0k299.0k674.0k629.0k732.0k941.0k769.0k

Current Assets

68.1m151.8m190.2m184.1m200.2m171.5m159.5m136.5m163.5m166.3m158.8m

PP&E

535.0k7.4m7.3m8.2m12.3m14.2m14.6m11.8m12.0m12.2m12.8m

Goodwill

18.6m18.6m18.6m18.6m18.6m18.6m

Total Assets

68.8m211.9m249.8m245.1m265.1m236.9m224.9m200.5m227.3m221.6m228.8m

Accounts Payable

1.4m24.9m25.0m32.0m44.7m38.1m37.3m37.1m24.3m28.5m34.2m

Short-term debt

4.6m5.4m6.7m13.6m13.6m11.8m20.4m11.9m12.1m18.3m17.4m

Current Liabilities

9.0m52.8m53.5m68.4m79.3m62.2m70.8m49.0m36.4m46.9m51.7m

Long-term debt

9.8m26.1m39.3m40.7m73.4m73.5m64.5m98.6m98.8m92.7m94.5m

Total Debt

14.4m31.6m46.0m54.3m87.1m85.3m85.0m110.5m111.0m111.1m111.9m

Total Liabilities

20.2m85.6m99.2m123.8m157.5m140.6m140.3m149.8m137.4m146.6m153.5m

Common Stock

30.0k50.0k239.0k404.0k541.0k830.0k551.0k828.0k558.0k570.0k79.0k

Preferred Stock

1.0k1.0k1.0k1.0k1.0k1.0k2.0k

Additional Paid-in Capital

152.2m304.9m346.6m338.3m374.3m397.9m408.6m414.9m439.3m446.0m485.2m

Retained Earnings

(103.7m)(257.2m)(274.6m)(301.7m)(333.1m)(354.8m)(371.4m)(394.9m)(408.0m)(420.7m)(448.6m)

Total Equity

48.6m126.3m150.6m121.3m107.5m96.3m84.6m50.7m89.8m75.0m75.3m

Debt to Equity Ratio

0.3 x0.2 x0.3 x0.4 x0.8 x0.9 x1 x2.2 x1.2 x1.5 x

Debt to Assets Ratio

0.2 x0.1 x0.2 x0.2 x0.3 x0.4 x0.4 x0.6 x0.5 x0.5 x

Financial Leverage

1.4 x1.7 x1.7 x2 x2.5 x2.5 x2.7 x4 x2.5 x3 x3 x

Fortress Biotech Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019

Net Income

(99.8m)(141.9m)(101.7m)

Depreciation and Amortization

2.8m1.4m1.9m

Accounts Receivable

(5.9m)2.3m(8.1m)

Inventories

32.0k(507.0k)(179.0k)

Accounts Payable

9.7m4.7m2.1m

Cash From Operating Activities

(85.4m)(98.8m)(95.0m)

Purchases of PP&E

(2.1m)(7.1m)(2.3m)

Cash From Investing Activities

(41.6m)18.8m20.1m

Long-term Borrowings

(3.6m)(1.9m)(134.0k)

Dividends Paid

(299.0k)(2.3m)(2.6m)

Cash From Financing Activities

154.2m50.6m146.7m

Net Change in Cash

27.1m(29.4m)71.9m

Fortress Biotech Ratios

USDY, 2020

EV/EBIT

-10.4 x

EV/CFO

-10.2 x

Financial Leverage

3 x